Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients
Authors:
- Charlie MarvalimCMCharlie Marvalim
- Jing Xiang Gimson WongJWJing Xiang Gimson Wong
- Natalia SutimanNSNatalia Sutiman
- Wan Teck LimWLWan Teck Lim
- Shao Weng TanSTShao Weng Tan
- Ravindran KanesvaranRKRavindran Kanesvaran
- Quan Sing NgQNQuan Sing Ng
- Amit JainAJAmit Jain
- Mei Kim AngMAMei Kim Ang
- Wan Ling TanWTWan Ling Tan
- Chee Keong TohCTChee Keong Toh
- Eng Huat TanETEng Huat Tan
- 1 March 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 27 (3) , 120-123
Abstract
The critical role of lysine demethylase 4A (KDM4A), in regulating chromatin structure and consequently in driving cellular proliferation and oncogenesis has been the focus of recent studies. Non-small-cell lung cancer (NSCLC) patients with adenocarcinoma histology who were homozygous for KDM4A single nucleotide polymorphism (SNP)-A482 (rs586339) were recently shown to have significantly worse overall survival (OS) compared with patients with the wild-type or the heterozygous genotype at this locus (hazard ratio=1.68, P=0.042). In the current study, we investigated the association between the same polymorphism with OS in our Asian NSCLC-adenocarcinoma patients comprising Chinese (N=572), Malays (N=50), and Indians (N=22). KDM4A SNP-A482 genotype status was determined by Sanger sequencing. OS was calculated from the date of diagnosis to date of death or censored at the date of last follow-up. Kaplan–Meier analysis, log-rank test, and Cox regression methods were utilized to evaluate OS outcomes. KDM4A SNP-A482 had a minor allele (C) frequency of 18.8% and a major allele (A) frequency of 81.2% in our Asian NSCLC (adenocarcinoma) patients. However, the OS in our Asian NSCLC patients homozygous for KDM4A SNP-A482 was not significantly different from those who were wild type or heterozygous at this locus [CC vs. AA/AC: median OS (95% confidence interval): 40.2 (18.7–61.6) vs. 29.6 (26.9–32.3) months; P=0.858]. The results remained statistically nonsignificant even after adjustment for epidermal growth factor receptor mutational status, suggesting that KDM4A SNP-A482 does not significantly influence OS in Asian NSCLC patients.Keywords
This publication has 18 references indexed in Scilit:
- The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpressionBiochemistry and Cell Biology, 2013
- Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G1/S transitionCancer Letters, 2013
- Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological ImpactMolecular Cell, 2012
- The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cellsJournal of Cellular Biochemistry, 2011
- The Histone Demethylase JMJD2B Plays an Essential Role in Human Carcinogenesis through Positive Regulation of Cyclin-Dependent Kinase 6Cancer Prevention Research, 2011
- The Histone Demethylase JMJD2B Is Regulated by Estrogen Receptor α and Hypoxia, and Is a Key Mediator of Estrogen Induced GrowthCancer Research, 2010
- Activation of androgen receptor by histone demethylases JMJD2A and JMJD2DBiochemical and Biophysical Research Communications, 2007
- Dynamic Regulation of Histone Lysine Methylation by DemethylasesMolecular Cell, 2007
- The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36Nature, 2006
- Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding ProteinJournal of Biological Chemistry, 2005